Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway

Heng Cheng, Youhoon Chong, Inkyu Hwang, Ali Tavassoli, Yan Zhang, Ian A. Wilson, Stephen Benkovic, Dale L. Boger

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The synthesis and evaluation of 10-methanesulfonyl-DDACTHF (1), 10-methanesulfonyl-5-DACTHF (2), and 10-methylthio-DDACTHF (3) as potential inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) are reported. The compounds 10-methanesulfonyl-DDACTHF (1, Ki = 0.23 μM), 10-methanesulfonyl-5-DACTHF (2, Ki = 0.58 μM), and 10-methylthio-DDACTHF (3, Ki = 0.25 μM) were found to be selective and potent inhibitors of recombinant human GAR Tfase. Of these, 3 exhibited exceptionally potent, purine sensitive growth inhibition activity (3, IC 50 = 100 nM) against the CCRF-CEM cell line being 3-fold more potent than Lometrexol and 30-fold more potent than the parent, unsubstituted DDACTHF, whereas 1 and 2 exhibited more modest growth inhibition activity (1, IC 50 = 1.0 μM and 2, IC50 = 2.0 μM).

Original languageEnglish (US)
Pages (from-to)3577-3585
Number of pages9
JournalBioorganic and Medicinal Chemistry
Volume13
Issue number10
DOIs
StatePublished - May 15 2005

Fingerprint

Phosphoribosylglycinamide Formyltransferase
Biosynthetic Pathways
Hydroxymethyl and Formyl Transferases
Growth
Inhibitory Concentration 50
Cells
Cell Line
10-methanesulfonyl-5-DACTHF
10-methanesulfonyl-DDACTHF
10-methylthio-DDACTHF
purine

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Pharmaceutical Science
  • Drug Discovery
  • Clinical Biochemistry
  • Organic Chemistry

Cite this

Cheng, Heng ; Chong, Youhoon ; Hwang, Inkyu ; Tavassoli, Ali ; Zhang, Yan ; Wilson, Ian A. ; Benkovic, Stephen ; Boger, Dale L. / Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway. In: Bioorganic and Medicinal Chemistry. 2005 ; Vol. 13, No. 10. pp. 3577-3585.
@article{c63bc8b070754f379017e675ad2c03fd,
title = "Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway",
abstract = "The synthesis and evaluation of 10-methanesulfonyl-DDACTHF (1), 10-methanesulfonyl-5-DACTHF (2), and 10-methylthio-DDACTHF (3) as potential inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) are reported. The compounds 10-methanesulfonyl-DDACTHF (1, Ki = 0.23 μM), 10-methanesulfonyl-5-DACTHF (2, Ki = 0.58 μM), and 10-methylthio-DDACTHF (3, Ki = 0.25 μM) were found to be selective and potent inhibitors of recombinant human GAR Tfase. Of these, 3 exhibited exceptionally potent, purine sensitive growth inhibition activity (3, IC 50 = 100 nM) against the CCRF-CEM cell line being 3-fold more potent than Lometrexol and 30-fold more potent than the parent, unsubstituted DDACTHF, whereas 1 and 2 exhibited more modest growth inhibition activity (1, IC 50 = 1.0 μM and 2, IC50 = 2.0 μM).",
author = "Heng Cheng and Youhoon Chong and Inkyu Hwang and Ali Tavassoli and Yan Zhang and Wilson, {Ian A.} and Stephen Benkovic and Boger, {Dale L.}",
year = "2005",
month = "5",
day = "15",
doi = "10.1016/j.bmc.2004.12.004",
language = "English (US)",
volume = "13",
pages = "3577--3585",
journal = "Bioorganic and Medicinal Chemistry",
issn = "0968-0896",
publisher = "Elsevier Limited",
number = "10",

}

Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway. / Cheng, Heng; Chong, Youhoon; Hwang, Inkyu; Tavassoli, Ali; Zhang, Yan; Wilson, Ian A.; Benkovic, Stephen; Boger, Dale L.

In: Bioorganic and Medicinal Chemistry, Vol. 13, No. 10, 15.05.2005, p. 3577-3585.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design, synthesis, and biological evaluation of 10-methanesulfonyl-DDACTHF, 10-methanesulfonyl-5-DACTHF, and 10-methylthio-DDACTHF as potent inhibitors of GAR Tfase and the de novo purine biosynthetic pathway

AU - Cheng, Heng

AU - Chong, Youhoon

AU - Hwang, Inkyu

AU - Tavassoli, Ali

AU - Zhang, Yan

AU - Wilson, Ian A.

AU - Benkovic, Stephen

AU - Boger, Dale L.

PY - 2005/5/15

Y1 - 2005/5/15

N2 - The synthesis and evaluation of 10-methanesulfonyl-DDACTHF (1), 10-methanesulfonyl-5-DACTHF (2), and 10-methylthio-DDACTHF (3) as potential inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) are reported. The compounds 10-methanesulfonyl-DDACTHF (1, Ki = 0.23 μM), 10-methanesulfonyl-5-DACTHF (2, Ki = 0.58 μM), and 10-methylthio-DDACTHF (3, Ki = 0.25 μM) were found to be selective and potent inhibitors of recombinant human GAR Tfase. Of these, 3 exhibited exceptionally potent, purine sensitive growth inhibition activity (3, IC 50 = 100 nM) against the CCRF-CEM cell line being 3-fold more potent than Lometrexol and 30-fold more potent than the parent, unsubstituted DDACTHF, whereas 1 and 2 exhibited more modest growth inhibition activity (1, IC 50 = 1.0 μM and 2, IC50 = 2.0 μM).

AB - The synthesis and evaluation of 10-methanesulfonyl-DDACTHF (1), 10-methanesulfonyl-5-DACTHF (2), and 10-methylthio-DDACTHF (3) as potential inhibitors of glycinamide ribonucleotide transformylase (GAR Tfase) and aminoimidazole carboxamide ribonucleotide transformylase (AICAR Tfase) are reported. The compounds 10-methanesulfonyl-DDACTHF (1, Ki = 0.23 μM), 10-methanesulfonyl-5-DACTHF (2, Ki = 0.58 μM), and 10-methylthio-DDACTHF (3, Ki = 0.25 μM) were found to be selective and potent inhibitors of recombinant human GAR Tfase. Of these, 3 exhibited exceptionally potent, purine sensitive growth inhibition activity (3, IC 50 = 100 nM) against the CCRF-CEM cell line being 3-fold more potent than Lometrexol and 30-fold more potent than the parent, unsubstituted DDACTHF, whereas 1 and 2 exhibited more modest growth inhibition activity (1, IC 50 = 1.0 μM and 2, IC50 = 2.0 μM).

UR - http://www.scopus.com/inward/record.url?scp=17444399660&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=17444399660&partnerID=8YFLogxK

U2 - 10.1016/j.bmc.2004.12.004

DO - 10.1016/j.bmc.2004.12.004

M3 - Article

VL - 13

SP - 3577

EP - 3585

JO - Bioorganic and Medicinal Chemistry

JF - Bioorganic and Medicinal Chemistry

SN - 0968-0896

IS - 10

ER -